HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $70
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $60 to $70.
HC Wainwright & Co. analyst Emily Bodnar maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $60 to $70.